Non Small Cell Lung Cancer Clinical Trial
Official title:
A Phase II Study of Erlotinib and Predictive Markers as First-line Treatment of Advanced Non-small Cell Lung Cancer for Patients Unfit for Chemotherapy
Verified date | December 2014 |
Source | Rigshospitalet, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | Denmark: Danish Medicines Agency |
Study type | Interventional |
A phase II study of Tarceva (Erlotinib) and predictive markers as first-line treatment of
advanced non-small cell lung cancer for patients unfit for chemotherapy (NSCLC) Clinical
Phase II Stage IIIB or IV non-small cell lung cancer (NSCLC) Primary end point: Disease
control rate (= CR+PR and SD at 8 weeks /patients). Secondary end point: Safety (Serious
Adverse Events, Adverse Events leading to premature withdrawal, unexpected TarcevaTM related
AEs) .Correlation of EGFR expression rate (HER1) and FISH potentially predictive for
response.
An open-label, non randomized, multicenter, clinical trial of TarcevaTM as single agent The
sample size is 29 patients in 2 stages and based on Simon´s optimal 2 stage design. Stage 1
will accrue 10 patients, if less than 1 response is observed the study will stop; if more
than 1 response is observed the accrual will continue up till 29 patients. A total of 29
patients would be entered and the treatment will be declared to have sufficient activity to
deserve further attention if at least 5 patients obtain disease control.
Status | Terminated |
Enrollment | 24 |
Est. completion date | August 2010 |
Est. primary completion date | February 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histological or cytological documented diagnosis of inoperable, locally advanced, recurrent or metastatic (Stage IIIB or Stage IV) NSCLC. - Chemo-naïve patients. - Patients who are in the investigator's opinion not medically suitable for chemotherapy. - Measurable disease according to the RECIST criteria. - ECOG performance status of 0 - 3. - Life expectancy of at least 12 weeks. - Patients must be able to take oral medication. - Serum calcium within normal ranges - = 4 weeks since prior surgery or radiation therapy - For all females of childbearing potential a negative pregnancy test must be obtained within 48 hours before starting therapy and must use effective contraception - 18 years of age or older - Written (signed) Informed Consent to participate in the study Exclusion Criteria: - Prior systemic antitumor therapy - Any unstable systemic disease which according to the investigator contraindicates the use of the study drug render the subject at high risk from treatment complications (including active infection, unstable angina, myocardial infarction within the previous month, inflammatory bowel disease, hepatic disease with serum bilirubin = 2 upper limit of normal (ULN) or AST and/or ALT = 2 x ULN (or = 5 x ULN if clearly attributable to liver metastasis), renal disease with acute renal failure or serum creatinine = 5 x ULN. - Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer). - Nursing mothers or pregnant woman. - Hypersensitivity to Tarceva or co-formulants. - Patients with brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation. - Patients with brain metastasis or spinal cord compression that not are in a stable condition despite treatment with steroids. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Oncology, Århus University Hospital | Århus | |
Denmark | Department of Oncology, Rigshospitalet | Copenhagen | |
Denmark | Department of Oncology, Odense University Hospital | Odense |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark | Hoffmann-La Roche |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease control rate | 2010 | No | |
Secondary | To investigate the tolerability and safety of erlotinib in patients, who can not receive chemotherapy, by registration of side-effects. | 2010 | No | |
Secondary | Correlation of EGFR expression rate and FISH potentially predictive for response | 2010 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |